Jo, Yunju Sim, Hye-In Yun, Bohwan Park, Yoon Jin, Hyung-seung 2024-10-10T08:00:16Z 2024-10-10T08:00:16Z 2024-10-10 2024-10 1226-3613 https://pubs.kist.re.kr/handle/201004/150780 Cancer immunotherapy aims to initiate or amplify immune responses that eliminate cancer cells and create immune memory to prevent relapse. Immune checkpoint inhibitors (ICIs), which target coinhibitory receptors on immune effector cells, such as CTLA-4 and PD-(L)1, have made significant strides in cancer treatment. However, they still face challenges in achieving widespread and durable responses. The effectiveness of anticancer immunity, which is determined by the interplay of coinhibitory and costimulatory signals in tumor-infiltrating immune cells, highlights the potential of costimulatory receptors as key targets for immunotherapy. This review explores our current understanding of the functions of CD2 and CD226, placing a special emphasis on their potential as novel agonist targets for cancer immunotherapy. CD2 and CD226, which are present mainly on T and NK cells, serve important functions in cell adhesion and recognition. These molecules are now recognized for their costimulatory benefits, particularly in the context of overcoming T-cell exhaustion and boosting antitumor responses. The importance of CD226, especially in anti-TIGIT therapy, along with the CD2-CD58 axis in overcoming resistance to ICI or chimeric antigen receptor (CAR) T-cell therapies provides valuable insights into advancing beyond the current barriers of cancer immunotherapy, underscoring their promise as targets for novel agonist therapy. Immunotherapy, including immune checkpoint inhibitors and adoptive T-cell therapy, has transformed cancer treatment, yet durable responses are limited to a minority of patients. Anticancer immunity, shaped by co-inhibitory and co-stimulatory signals in tumor-infiltrating immune cells, underscores co-stimulatory receptors as promising targets for immunotherapy. This review explores the roles of CD226 and CD2 in regulating T cell responses, particularly in tumor immunity. CD2 and CD226, primarily on T and NK cells, are crucial for cell adhesion and recognition, known for their role in overcoming T cell exhaustion and boosting anti-tumor responses. The review examines their potential as targets in novel cancer immunotherapeutic strategies. This summary was initially drafted using artificial intelligence, then revised and fact-checked by the author. English Springer Nature Revisiting T-cell adhesion molecules as potential targets for cancer immunotherapy: CD226 and CD2 Article 10.1038/s12276-024-01317-9 1 Experimental & Molecular Medicine, v.56, no.10, pp.2113 - 2126 Experimental & Molecular Medicine 56 10 2113 2126 Y scie scopus kci ART003135306 001322480100006 2-s2.0-85205371573 Biochemistry & Molecular Biology Medicine, Research & Experimental Biochemistry & Molecular Biology Research & Experimental Medicine Review CYTOPLASMIC DOMAIN DNAM-1 CD226 NECTIN-2 CD112 PVR CD155 FUNCTIONAL-CHARACTERIZATION GLY307SER ASSOCIATION REGULATES ANTITUMOR DENDRITIC CELLS ACTIVATING RECEPTOR CD226 LIPID RAFT RECRUITMENT